The increasing conduct of health systems research in low and middle-income countries (LMICs) has not been matched by concurrent work to clarify the field's ethical dimensions.
Introduction
Externally-funded health systems research (HSR) is increasingly being conducted in low and middle-income countries (LMICs) (Bennett et al., 2008) . HSR has been defined as:
a multidisciplinary field of health research which studies governance, financial and delivery arrangements for health care and public health services, implementation considerations for reforming or strengthening these arrangements, and broader economic, legal, political and social contexts in which these arrangements are negotiated and operate. The purpose of health systems research is to improve the understanding and performance of health systems. (Hoffman et al., 2012, p. 18) It is a much broader field than health services research, which some suggest comprises a sub-domain of HSR (Hoffman et al., 2012) . HSR focuses on all health systems components, which include but are not limited to service delivery, and their interactions.
1 Thus far, the geographical focus of HSR has primarily been LMICs, though it can and has been performed in high-income countries (Gilson, 2012; Sheikh et al., 2011) . These actions stemmed from concern that external actors' prolonged emphasis on vertical programs had significantly weakened LMIC health systems, creating substantial bottlenecks in efforts to meet global health objectives (e.g. increased uptake of antiretroviral therapy and expanded immunisation coverage in LMICs) and to achieve broader targets like the to channel a somewhat larger amount of resources to HSR in LMICs and promoted conceptual work to better define the aims, scope, and methods of the field (Bennett et al., 2008; Mills, 2011; Sheikh et al., 2011) . This reflects the fact that HSR is an evolving field, whose boundaries, definitions, and characteristics are still being discussed and debated (Hoffman et al., 2012) .
There has been some work done on the ethics of health services research in highincome countries, which focuses on the ethical issues inherent in employing qualitative methods and cluster trials (Conrad & Edwards, 2011; Edwards, Braunholtz, Lilford, & Stevens, 1999; Richards & Schwartz, 2002; Weijer et al., 2011) . Scholarship has also assessed the need for informed consent in health services research projects that rely on population-based records (Cassell & Young, 2002; Meslin, 2006) . However, despite the growth of interest in HSR in LMICs, there has been less concurrent effort to clarify the field's ethical dimensions (Mills, 2011) . More importantly, there has been limited consideration of the ethics of externally-funded HSR in LMICs by the field of bioethics. At most, there has been discussion in the bioethics literature related to ethics of cluster trials in LMICs and the use of financial incentives as interventions in LMICs (London, Borasky, & Bhan, 2012; Orsin et al., 2009; Weijer et al., 2011 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 We acknowledge that some of the ethical concepts (e.g. informed consent) discussed in the paper and their application may be relevant to HSR in high-income countries. There is not necessarily a clear boundary between the considerations that arise in HSR in high-income country versus LMIC settings in relation to shared ethical concepts.
Bioethics research is needed to characterise the considerations that are pertinent in both settings to make the boundary clearer. This paper, we hope, contributes to such an evolving process by describing some of the considerations that are relevant in LMICs. Although the HSR terrain is still being mapped out, consensus is emerging that the field is delimited, not by its methods but by the topics and scope of its research questions (Gilson, 2012; Mills, 2011; Sheikh et al., 2011 disease focus, but they frequently address aspects of the health system like human resources or financing that generate impacts across a broad range of diseases, yielding public health improvements. HSR can also be exploratory and descriptive, which means no intervention is actually assessed as part of the research (Gilson, 2012).
Need for health systems research ethics
The research participants of HSR are often not individuals but groups of people.
Interventions are frequently targeted to entire households, clinics, schools, neighbourhoods, or communities. It is not uncommon for the unit of intervention to be different from the unit from which data are collected in HSR. For example, in a study evaluating a conditional cash transfer intervention to improve the uptake of maternal and child health services, the intervention is randomised at the municipality level but evidence on the use of maternal and child health services is collected from individuals (i.e. pregnant women and new mothers within those municipalities) (Morris, Flores, Olinto, & Medina, 2004) . This raises the question of whether research participants encompass all members of participating municipalities or the pregnant women and new mothers from whom data is collected (Weijer et al., 2011) . In clinical research, the units of intervention allocation and data collection are generally the same: individual human research participants.
Workshop participants felt that these additional dimensions of HSR were sufficient to give rise to a range of ethical considerations in HSR in LMICs that would not necessarily need to be addressed in international clinical research, though they recognised that some ethical issues would be shared. Indeed, numerous ethical questions were put forward by workshop attendees as being relevant to HSR in LMICs that were not as central to the ethics of international clinical research. Furthermore, they recognized that HSR in LMICs is strongly affected by the context of research and that contexts of scarcity gives acuity to even those ethical issues that are more generally relevant. 
Unit of randomisation
Unlike clinical research, HSR is population-focused and, as a result, interventions are often tested by being randomised at the level of the district, community, or health institution rather than the individual level. In instances where the unit of randomisation is not the individual, ethical issues relating to informed consent are raised for HSR that are less straightforward than those arising in clinical studies. Where HSR interventions are allocated to households in particular districts or to health clinics and hospitals across a country, should researchers inform individuals that the study is going on? Should researchers be required to give individual patients or household members a choice to participate in the study? And when is individual informed consent necessary if 'gatekeepers' such as government officials, community leaders, school directors, or hospital administrators have already agreed for the intervention to be implemented in their environment or jurisdiction?
In clinical research, the general norm is for research to proceed in most cases with individual informed consent. However, workshop participants pointed out that, for certain systems level interventions, individual consent may be rendered meaningless where it is impossible or extremely difficult to avoid exposure to the intervention such as where a hospital is randomised to a study arm that involves a different type of staffing arrangement for emergency care. They also noted that many HSR studies might meet the criteria for a waiver of consent under the Code of Federal Regulations in the USA, but the appropriateness of those criteria for HSR would need to be analysed. Weijer et al. (2011) have previously argued that informed consent may not be required for cluster trials that do not randomise interventions amongst individuals and meet waiver requirements.
Beyond relying on existing regulations to determine when informed consent is required, a distinction between informing individuals of study interventions and gaining informed consent was put forward by workshop participants. This distinction is based on an understanding of informed consent as having two components: 1) providing information about a study and the intervention it is testing (where applicable), and 2) obtaining agreement from prospective participants that they will voluntarily enter a study based on that information. Where HSR interventions are not randomised at the individual level, while seeking consent from individuals may not be feasible, researchers may still be able to inform patients or community members that the study is taking place. By informing patients or community members that a study is going on, these individuals then, in many cases, may have the option not to participate and can make the choice to opt-out by, for example, seeking medical care for their illness at a hospital in a non-participating district.
In determining when individual level consent still ought to be required, workshop attendees proposed that researchers might consider whether a study intervention alters the local environment in a way that patients or citizens would normally be consulted about prior to implementation. in contexts where such tradition is both strong and involves fair process.
Nature of the intervention: Novel delivery methods
Where HSR assesses the efficacy of new delivery methods for particular health services, nuanced ethical issues related to equipoise and the standard of care provided to control/comparison groups are especially prominent. There was debate amongst workshop participants over when conditions of equipoise actually exist in HSR. The question was raised: if the health care being delivered has been proven effective and the delivery method has been shown efficacious for other medical interventions, are conditions of equipoise met?
It was argued that, when there was more than a 50-50 chance that the intervention would work, rather than doing research, the delivery strategy should simply be rolled out by the Ministry of Health and evaluated at baseline and at time points afterwards. Such a comment highlights that the distinction between HSR and program development and evaluation can get quite blurry. In certain instances, it may not be clear which option is called for. For example, is an efficacy trial or a feasibility evaluation needed when a delivery mechanism has been shown to work multiple times but local policymakers want further evidence that it works in their specific setting?
Here, workshop participants highlight that HSR (where delivery methods are tested) may still be associated with less equipoise than clinical trials when the health care or services being delivered are generally known to be effective. They purported that this has implications for what control groups are owed during HSR. Debate ensued on the matter of whether it is ethical to refrain from providing control groups with access to the health care or knowledge that people in the control group will become sick or even die, it is unethical for researchers not to take steps to prevent it, where doing so is not hugely burdensome for them (Singer, 1972) . Those with an opposing view asserted that delivering health care to the control group fell beyond the scope of researchers' obligations, suggesting it was the responsibility of the Ministry of Health and local health system. The moral distinction between acts and omissions-causing harm versus seeing suffering and not doing anything to address it-was also put forward as being applicable here. In effect, some proposed that researchers should only have an ethical obligation to provide care to control villages if they were the primary agents responsible for the people not having access to such care.
To address conditions of lesser equipoise in HSR, a stepped wedge design may be used. Such a design entails progressively rolling out the study intervention (and, in effect, the health care provided with it) to participating villages so that even control villages receive the intervention by the end of a study. Although the study intervention would have been randomised, all villages in a study would have received it in the end. With stepped-wedge designs, however, individuals can still have negative health effects even with delayed provision if there is a time-window for individual benefit. As such, some people in villages that received the study intervention later may still suffer due to a lack of health care, but it may be a lower number than if a stepped-wedge design was not used (assuming the delivery method under study was efficacious). However, by analogy, were the Ministry of Health to take on the responsibility of improving access to health care, any initiative it 
Nature of the intervention: Creating demand for existing services
Where HSR assesses the efficacy of interventions that are designed to create population demand, distinctive ethical considerations related to fairness and justice, risk, and autonomy may arise. Being responsive to the particular conditions of host communities or districts means that HSR should develop and test methods to improve access to health services that reflect the specific barriers to access experienced in those settings. Where the study intervention is a financial incentive to promote the use of certain health services, financial barriers to accessing those services should be strongly prevalent in host communities or districts. For example, to ensure the responsiveness of voucher schemes harmful than beneficial to test it there. In response, it was suggested that the cost of paying people to access services might be less than the costs associated with people not accessing those same services. In the case of a maternal and child voucher program, for example, a LMIC government might be able afford to keep the program running based on the savings generated from not having to address more serious maternal and child health conditions and their associated social and economic costs. To assess the potential sustainability of a demand-side intervention in particular host communities, costing studies should be conducted to provide relevant information for ethical analysis.
An important risk to consider in studies testing demand-side interventions is their potential to negatively impact the supply-side. Workshop participants questioned the ethics of introducing a demand-side intervention when it was clear that the supply-side would not be able to cope with its effects. They further suggested that, where it is known that increased demand will substantially burden or overwhelm local health services, there is an obligation to strengthen the supply-side as part of the intervention. For these particular contexts, workshop participants recommended redesigning studies, contending that the intervention under study may include a package to strengthen both households' demand for services and the local health care facilities' capacity to supply them. In other contexts, where the risk is lower, it may be sufficient to include monitoring for supply-side burdens as part of the study design.
Finally, workshop participants considered whether a financial incentive intervention like a voucher program was autonomy-reducing or autonomy-promoting. In clinical trials, concerns have been raised that offering financial incentives to participate can undermine individual autonomy. People are swayed to behave in ways that they otherwise wouldn't were it not for the monetary inducement. In a recent article, however, London et al. (2012) asserted that, when financial incentives encouraging specific health-promoting behaviours are tested in research, they have the potential to enhance individual autonomy. In accordance with this view, workshop participants felt that voucher schemes can strengthen recipients' autonomy if they increase the range of opportunities available to them. Voucher schemes generally afford participants a greater chance to do things that they want to do and that they otherwise would not have been able to achieve such as accessing maternal and child health services.
Additionally, the intent behind a financial incentive was identified as being a morally relevant consideration in determining whether the incentive is autonomy-reducing or autonomy-promoting. Where financial incentives serve to entice people to face risks that they otherwise would not, they are more likely to undermine autonomy. Where financial incentives serve to expand individuals' opportunity range and help them achieve goals/benefits that they desire, such incentives can enhance autonomy. Nonetheless, other 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Ethical oversight of HSR
Workshop participants raised the concern that, by relying on ethical guidelines for international biomedical research, IRBs may fail to consider how ethical constructs should best be applied to HSR. Suggestions were made to improve IRB oversight of HSR. First, it was recommended that a practical decision guide be developed for IRBs to guide their review of HSR projects in LMICs. Since HSR is a very broad field, there is a lot of variation amongst projects in terms of their features such as, the nature of the intervention being tested, the level of randomisation, and the level of data collection. To perform a comprehensive assessment, IRBs might classify HSR projects according to their features and then consider the ethical constructs associated with each feature. A decision tool containing targeted questions can possibly further guide IRBs on the ethical issues that arise in relation to each construct ( brought in to evaluate a systems level intervention after it has been implemented in a LMIC.
The researchers had no control over what the intervention was or which communities were selected to participate in the study; and they are not responsible for delivering the intervention. In scenario 2, external researchers have played a significant role in designing and bringing an intervention into host communities. They have trained local health workers to deliver the intervention and to explain it to the community; and they have been involved in the project at every stage. In this scenario, the IRB has considerable potential for oversight because researchers are in control of all phases of the project. In contrast, in scenario 1, the IRB's ability to require alterations to aspects of the intervention project that are ethically troubling is much weaker. At the workshop, it was suggested that IRBs may limit their analysis to those aspects of studies that researchers are in a position to influence.
Finally, it was recommended that HSR projects involving human subjects be subject to careful IRB oversight, particularly where it is unclear if the project constitutes research or practice. The boundaries between HSR and program development and evaluation are often not well-defined. Where work is deemed practice-based rather than research-based, it is typically not subject to ethical review, making the distinction seemingly important. However, we take the position that ethical discussions can be helpful, regardless of whether activities are classified as research or practice. This is in accordance with comments made recently by Kass et al. (2013) and MacQueen and Buehler (2004, p. 931 ) that call for 'developing methods of oversight for public health investigations that are less dependent on the research versus practice distinction and more geared to assessing the level of risk and ensuring ethical conduct.' 2 We recognise that health services research has long been conducted in high-income countries, though HSR, with its broader scope, is only starting to be.
A call to action
3 In LMIC contexts, the choice of consent strategy must be informed not only by professional, institutional and environmental norms but also by social and political influences (negative and positive) and by the degree of trust in social/health systems and institutions. This is to reduce the potential for the consent strategy to further legitimize and entrench norms that relate to a lack of transparency in some contexts. Travis P., Bennett S., Haines A., Pang T., Bhutta Z, Hyder, A.A.,…Evans, T. (2004) .
Overcoming health-systems constraints to achieve the Millennium Development • Will participants in the control group receive the health care or services provided to the intervention group without researchers' intervention? • What will happen to participants in the control group if they do not receive the care or services? • Should the health care or services provided to the intervention group be provided to the control group? • Would a stepped wedge design reduce the risk to the control group? Could it be employed in this study? Risk 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
